Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association

AI Briefing

• – Alnylam partners with Viz.ai to improve ATTR-CM care coordination, will support American Heart Association's mission to promote cardiovascular health.
• – The collaboration aims to accelerate earlier recognition and improve treatment outcomes for patients with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).
• – The partnership will focus on enhancing patient engagement and education, as well as developing data-driven approaches to care coordination and outcomes measurement.